Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Internal Medicine
•
Myeloproliferative Neoplasms
•
Hematology
How do you manage and/or prevent ruxolitinib withdrawal syndrome?
Answer from: Medical Oncologist at Community Practice
Generally, tapering over a week or two is the best way to prevent it. If immediate discontinuation is needed, can consider using steroids.
Sign in or Register to read more
14673
Related Questions
For patients with essential thrombocythemia who develop venous thrombosis in the setting of elevated platelet counts, would you continue lifelong anticoagulation even after cytoreduction is achieved?
Would you change therapy for a CML patient in hematologic remission on imatinib found with positive qualitative BCR-ABL1 for the p230 protein?
Under which circumstances would you prefer ropeginterferon over hydroxyurea for patients with Polycythemia Vera?
How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?
How do you decide between using ropeginterferon alfa-2b and peginterferon alfa-2a in MPN?
For patients with essential thrombocythemia already on prophylactic dose DOACs, do you defer starting aspirin?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?
Would you consider splenic radiation in stage IV CD5+ DLBCL involving the bone marrow in patients who initially presented with symptomatic splenomegaly, anemia, and thrombocytopenia but achieved complete response on PET after 6 cycles of R-miniCHOP?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?